CD44 and cancer: The first one was employed by Wang and colleagues, who developed hyaluronic acid-block-poly(D,L-lactide-co-glycolide) (HA-b-PLGA) micelles encapsulating PPIX to create a drug delivery system of improved PDT specificity and effectiveness targeting CD44-overexpressing cancer cells [37].